Patents Assigned to HuidaGene Therapeutics Co., Ltd.
  • CRISPR-CAS12i systems
    Patent number: 11649444
    Abstract: The present disclosure provides a Cas12i protein (e.g., non-naturally occurring, engineered) comprising an amino acid sequence having at least about 80% (e.g., at least about any of 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100%) identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 1-10 (preferably, SEQ ID NOs: 1-3 and 6, and more preferably, SEQ ID NO: 1).
    Type: Grant
    Filed: August 15, 2022
    Date of Patent: May 16, 2023
    Assignee: HuidaGene Therapeutics Co., Ltd.
    Inventors: Hainan Zhang, Xiangfeng Kong, Qijia Chen